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Introduction 
Cryoglobulins are immunoglobulins (Ig) that precipitate at temperatures lower than 
37~ with resolution upon warming [1-3]. Since their initial characterization by
Lerner et al. [1 ], it has been recognized that they are not a single distinct group of Ig, 
but heterogeneous with respect o their composition and physical properties. Cryo- 
globulins can be classified into three types [3] according to the presence in the cryo- 
precipitates of: monoclonal lg (type I), both monoclonal and polyclonal Ig (type II), 
or polyclonal ig with or without other serum proteins or exogenous antigens (type 
III). Monoclonal type I cryoglobulins are mostly associated with various lymphopro- 
liferative disorders. Mixed type 1I or type III cryoglobulins are often found in serum 
from patients with atitoimmune diseases uch as systemic hipus erythematosus and 
rheumatoid arthritis or with a variety of chronic infectious diseases. 
Clearly, the interaction between Ig molecules plays a critical role in the formation 
of cryoglobulins, ince the sole or major components of a vast maiority of cryoglob- 
ulins are lg. The demonstration f rheumatoid factor (RF) and/or anti-idiotypic-like 
activity in IgM present in mixed cryoglobulins suggests the involvement of immune 
mechanisms in the generation of mixed cryoglobulins [2-6]. However, one should be 
aware that mixed cryoglobulins could be generated following in vitro, but not in vi- 
vo, interaction of low-affinity IgM RF with IgG complexes during the incubation of 
sera in test tubes at 4~ to isolate cryoglobulins. 
The molecular mechanisms responsible for the generation of type 1 monoclonal 
cryoglobulins are less clear. Available data suggest that several different mechanisms 
may be operative depending upori the particular cryoimmunoglobulins. Certain 
monoclonal Ig appear to form cryoprecipitates by self-association of Ig molecules 
via nonspecific physicochemical interaction [7-9], although a common physico- 
chemical mechanism underlying such interactions has not been elucidated. An alter- 
native, intriguing hypothesis is that cryoglobulins represent temperature-sensitive 
immunological interactions between the Fab region of the cryoprotein and antigenic 
determinants on the same molecules, i.e. an autoantibody-like reaction, as shown in 
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the two cases of monoclonal IgM cold agglutinins [10, 11]. It is of interest o note 
that similar cold agglutinins with cryoglobulin activity can be induced in mice after 
immunization with bacterial polysaccharide antigen [t2]. 
The presence of cryoglobulins could result in a wide range of vascular, renal and 
neurological complications, depending on their relative concentrations, their temper- 
ature-dependent solubility behavior, and the nature and type of proteins involved [3]. 
However, the precise cellular and molecular mechanisms involved in the induction of 
cryoglobulin-associated pathologies have not yet been well defined. This situation is 
at least partly due to the scarcity of relevant experimental models. Models of cwo- 
globulinemia should reproduce the appearance of one or other type of cryoglobulins, 
and some of the main pathological features usually observed in severe human cryo- 
globulinemia. In this article, we will focus on a unique physicochemical property of 
murine [gG3 that exhibit cryoglobulin activity, and discuss the pathogenesis of IgG3 
cryoglobulin-associated vascular leskms in mice. 
Cryoglobulin activity of murine lgG3 
IgG3: the major source of cryoglobulins in mice 
MRL-lpJ'/lpr autoimmune mice spontaneously develop a lupus-like syndrome char- 
acterized by unique immunopathological manifestations such as arthritic-like le- 
sions, necrotizing vascular lesions of the skin of ears and footpads, and severe glo- 
merulonephritis [13]. In parallel, they produce the most striking amounts of cryo- 
globulins among several upus-prone mice like (NZB x NZW)FI or BXSB mice 
[13, 14]. Cryoglobulins from MRL-lpr/lpr mice are composed almost exclusively of 
IgG of polyclonal origin. Strikingly, the IgG3 content of cryoglobulins i markedly 
enriched, as compared with other IgG subclasses [14]. This preferential participa- 
tion of IgG3 in the formation of polyclonat cryoglobulins i  not an exclusivity of 
autoimmune MRL-lpr/lpr mice, but can also be found in non-autoimmune mice af- 
ter polyclonal stimulation of B lymphocytes with bacterial ipopolysaccharides 
(LPS) or malaria parasites [14]. The absence of specific concentrations of anti-LPS, 
anti-malaria or anti-DNA antibodies in the respective cryoprecipitates xcludes a 
possible involvement of idiotype-anti-idiotype interaction i  the generation of these 
cryogtobutins. 
Since IgG3 is selectively concentrated in spontaneous and induced cryoglobulins, 
it is likely that the self-association a d subsequent cryoprecipitation f routine IgG3 
molecules i  the principal mechanism responsible for the generation of cryogtobulins 
in mice. To address this question, we have assessed the ability of IgG3 monoclonal 
antibodies (mAb) from autoimmune MRL-Ipr/lpr and (NZB x NZW)FI mice to gen- 
erate cryoglobulins. Out of 32 IgG3 mAb, independent of their immunological speci- 
ficities, 28 are capable of generating cryoglobulins composed exclusively of each 
IgG3 mAb without he intervention of any antigens, and are thus classified as type I 
monoclonal cryoglobulins [14-16]. The importance of the 73 constant (C73) region 
for cryoglobulin generation has been most directly demonstrated by Ig class-switch 
experiments: the cryoglobulin activity is gained following the lg class switch of mAb 
from tgM to lgG3, but lost following the class switch from [gG3 to IgM or lgG1 [14, 
17-191. The cryogtobulin activity of IgG3 is not a unique phenomenon i autoim- 
mune mice, because 6 of 8 lgG3 anti-diuitrophenyl (DNP) mAb derived from non- 
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autoimmune mice similarly develop cryoglobulins [20]. Such an activity of IgG3 
mAb has also been noticed by others [17, 21-23]. 
Fc-dependent self-association f IgG3 
Clearly, nmrine IgG3 have a unique physicochemical property which allows them to 
self-associate via their Fc-Fc interactions, independently of their specificities and or- 
igins. However, this unique property of murine IgG3 to self-associate is not limited 
to cryoprecipitating mAb. In fact, both cryoprecipitating and non-cryoprecipitating 
IgG3 mAb are able to interact with each other in a quantitatively similar manner, but 
not with other IgG subclasses [{4, 20]. This nonspecific IgG3-lgG3 interaction 
would account for the microaggregate formation observed in the first described mu- 
fine IgG3 myeloma protein, J606 [24]. The complete identity of the nucleotide se- 
quence of the CT3 region between the non-cryoprecipitable J606 protein and a cryo- 
precipitable 6-19 lgG3 RF mAb derived from MRL-lpr/Ipr mice rules out any ab- 
normality in the C~ region of either cryoprecipitable or non-cryoprecipitable IgG3 
protein [251. Thus, it is clear that the CT3 domain is necessary for the self-association 
of IgG3 mAb, but not sufficient in itself to determine cryoprecipitation. 
The molecular basis for the peculiar self-associating activity of muriae IgG3 is 
still unclem'. Because of the presence of a potential asparagine (N)-linked glycosyla- 
lion site oil the CH3 domain uniquely present in murine IgG3 [26], it has been specu- 
lated that the carbohydrate side chain possibly attached there may play a role in the 
formation of self-associating I G3 complexes. This possibility has been explored by 
analyzing the self-associating ability of a 5-7B IgG3 RF mutant mAb lacking the po- 
tential glycosylation site in the CH3 domain [27]. Although the author has claimed a 
significant reduction of the self-associating capacity of the mutant mAb, our recent 
study with the 6-19 IgG3 RF mAb has clearly shown that the self-associating ability 
is indistinguishable b tween wild-type and similarly mutated 6-19 RF mAb (unpub- 
lished observation), thus excluding the possible role of oligosaccharide chains in the 
CH3 domain in the lgG3 self-association. It should be mentioned that human IgG3 
have physicochemical properties imilar to those of murine IgG3. All the human 
IgG3 myeloma proteins tudied undergo aconcentration- and temperature-dependent 
aggregation, though not always cryoprecipitation [28-31]. Although this aggregating 
site is apparently localized in the Fd fragment of the human IgG3 heavy (H) chain 
[29], it remains to de determined whether this is also the case for murine IgG3. 
Role of the electrostatic charge in the H-chain variable region for IgG3 cryoglobulin 
activity 
Studies demonstrating inhibition of cryoprecipitation by anti-idiotypic antibodies 
[32] implicate some role of the variable (V) region. More significantly, it has been 
shown that the cryoprecipitation f anti-DNP IgG3 mAb is completely inhibited after 
the binding of anionic DNP-amino acid conjugates, and could be enhanced by the 
binding of cationic conjugates [20]. This is consistent with the idea that electrostatic 
interactions arc a significant factor in the precipitation process, as suggested by stud- 
ies on hunlan monoclonal cryoglobulins [8, 33, 34]. It is not surprising, however, 
that isoelectric point determinations of human monoclonal cryoglobulins and murine 
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Table 1. Role of the V H amino acid sequencea in the cryoglobulin activity of routine lgG3 mAb 
mAb ~ H-chain u L-chain Cryoglobutin 
6--19 6-19 (Q/K) 6-19 ++ 
6-19/9A6 6-19 (Q/K) 9 A6 ++ 
9A6 9A6 (E/A) 9A6 
9A6/6-19 9A6 (E/A) 6-19 - 
6- t 9Q6E,~23A 6--19 (E/A) 6-19 + 
CI1M C I1M (E/S) CI lM ++ 
DN6 DN6 (Q/K) DN6 - 
a 6-19/9A6 and 9A6/6-19 mAb are hybrid lgG3 antibodies. 6--19Q6Em,?A mAb is a 6-19 mutant mAb at 
the two V n residues 6 (glutamine to glutamic acid) and 23 (lysine to alanine) 
t, Amino acid residues at positions 6 and 23 are indicated in parentheses 
(Q glutamine, K tysine, E glutamic acid, A alalfine, S serine) 
lgG3 cryoglobulins fail to demonstrate differences between cryo- and non-cryoim- 
munoglobulins, because the presence of only a few electrostatic contacts may be all 
that is necessary to produce abnormal precipitation. 
Modulation of cryoglobulin activity as a result of the binding of charged hapten 
strongly suggests the implication of the V region sequences in cryoprecipitation f 
self-associating l G3 complexes, probably by providing additional positively charged 
residues. This idea is further supported by the demonstration that the cryoglobutin ac- 
tivity of IgG3 hybrid mAb composed of H-chains derived from either cryoglobulins 
or non-cryogtobulins is associated with the presence of H-chains derived from cryo- 
genic IgG3 mAb (Table 1). More specifically, residues 6 and 23 of the H-chain V do- 
main (Via) have been postulated to play a role in cryoprecipitation in a study compar- 
ing a panel of cryogenic and non-cryogenic monoclonal IgG3 [35]. Neutral glutarnine 
and cationic lysine are found at positions 6 and 23 in cryoglobulins, respectively, 
while their counterparts in non-cryoglobulins are more negatively charged (anionic 
glutamic acid at position 6 and a neutral amino acid at position 23). Further studies on 
tile 5-7B tgG3 RF monoclonal cryogtobulin mutated at position 6 or 23 have shown 
that V H residue 6 is an important factor in the cryoprecipitation f this [gG3 mAb 
[35]. However, although the residues 6 and 23 of V H are consistently observed to be 
more positively charged in the cryoprecipitatiug populations than in the non-cryopre- 
cipitating populations, there are exceptions. C l lM anti-DNP mAb exhibits a strong 
cryoglobulin activity, despite the fact that the residues at V H positions 6 and 23 are 
identical to those seen in non-cryoglobulins (Table 1). To the contrary, DN6 anti-IgGl 
mAb fails to cryoprecipitate, although glutamine and lysine are present at positions 6 
and 23, respectively, like cryogenic IgG3. In addition, we have observed that mutation 
of the 6--19 anti-IgG2a RF IgG3 mAb to non-cryoglobulm-like residues at positions 6
and 23 significantly, but not completely, reduces its cryoglobulin activity (Table 1). 
All these results indicate that the cryoglobulin activity of murine IgG3 is additionally 
determined by a factor other than the V H amino acid sequence. 
Role of galactosylation in IgG3 cryoglobulin activity 
IgG are glycoproteins, in which the CH2 domain of each H-chain bears an N-linked 
biantennary cttrbohydrate side chain. Each of these oligosaccharide chains, most of 
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IgG:' Galactosylated glycotbrms b Cryo 
GO GI G2 Gt+ G2 
(%) (%) (%) GO 
6-19 49.3 35.9 14.7 1.03 +++ 
LSD 36.4 49.3 I4.3 1.75 ++ 
6-19J 21.9 55.4 22.7 3.57 + 
a LSD mAb made of 6-19 lgG3 H-chains and J558 L-chains is obtained following the fusion of 6-19 hy- 
br~doma cel~s with J558L H-chain loss mutant myetoma ce{ts [43]. 6-I9I mAb made of the same H- and 
L-chains is generated following the transfection f J558L cells with the VDJu6.19_c.f3 plasmid [39]. 
b The molar atios of GO (no gatactose, t rminaling inN acetylglucosamine), G1 (one terminal gaIactose 
and one terminal N-acetylglucosamine) a d G2 (two terminal galactose r sidnes) glycoforms 
which are non-sialyated and neutral, ends either by two terminal gatactose residues 
(G2), one terminal galactose and one terminal N-acetylglucosamine (GI) or two ter- 
minal N~acetylglucosamines (GO) [36]. Since the level of terminal galactosylation is 
highly heterogeneous and substantially diminished in some diseases [36-38], differ- 
ences in the structure of carbohydrate side chains present in the CH2 domain of IgG 
may play an important role in determining the cryoglobulin activity of self-associat- 
ing lgG3 complexes. We have thus explored the possibility of a relationship between 
the cryoglobulin activity and the content of galactose residues in the oligosaccharide 
side chains on the H-chains. For this purpose, we have generated by two different 
means (cell fusion and transfection) two cell lines secreting hybrid IgG3 mAb made 
of the same H~chains (derived fiom 6-19 RF) with a potentially different galactosy- 
lation pattern (because of their synthesis in different myeloma cells) and of the same 
light (L) chains from J558 anti-~l-3 dextran antibodies [39]. The assessment of 
cryoglobulin activity of these two IgG3 mAb, identical in the amino acid sequence of 
their H- and L-chains, has demonstrated that the cryoglobulin activity is significantly 
reduced (approximately four times less) in the antibody having an increased propor- 
tion of galactosylated H-chains (Table 2). More recently, we have established an 
IgG3 mAb from mice expressing a 6-19 H-chain transgene, which bears the trans- 
genic 6-19 IgG3 H-chain and an endogenous L-chain, which is by chance identical 
to the 6-19 L-chain. Most strikingly, this IgG3 "6-19" rt~kb completely fails to ex- 
hibit cryoglobutin activity, and has again an increased content of galactosylated H-
chains (manuscript in preparation). This clearly indicates that the galactose content 
of oligosaccharide chains plays a key role in determining the cryoglobulin activity of 
IgG3 mAb. Although at present we do not have a good explanation for the role of 
galactose content in the lgG3 cryoglobulin activity, one likely explanation may be 
that the conformation of IgG3 molecules is somehow modified as a result of an in- 
creased content of galactose residues, thereby' reducing their cryoprecipitating activi- 
ty, as suggested by out recent study [39]. 
The observation that more galactosylated IgG3 have a lesser cryoglobulin activity 
raises an important question: what controls lgG galactosylation? It has been reported 
that B lymphocytes from patients with rheumatoid arthritis and ft'om MRL-lpr/Ipr 
mice have a reduced [3-1,4-galactosyltransferase activity [40-42], which may ac- 
count for an increased proportion of IgG lacking galactose in parallel to the progres- 
sion of their diseases [36, 38]. However, a marked, but not complete reduction in the 
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proportion of galactosylated IgG in mice deficient in 13-1,4-galactosyltransferase in- 
dicates the involvement of additional galactosyltransferase(s) for IgG galactosylation 
(manuscript in preparation). In addition, we have observed an increased percentage 
of non-galactosylated IgG in MRL-lpr/lpr mice, but not in MRL-+/+ mice or in 
C57BL/6 mice bearing the lpr mutation (manuscript in preparation). It thus appears 
that a decrease in the level of galactosylated IgG, putatively resulting from a de- 
creased level of galactosyltransferase in B lymphocytes, involves the lpr (Fas) muta- 
tion in combination with the MRL genetic background. This mutation probably re- 
suits in an increased life-span of activated B lymphocytes, because of functional de- 
fects in Fas-mediated apoptosis. In an autoimmune-prone g netic background such 
as MRL, expansion of some autoreactive B cell clones may be accompanied by a 
progressive decrease in galactosyltransferase ctivity of these aging cells, thus favor- 
ing the appearance of undergalactosylated autoantibodies, which could be more 
pathogenic because of a higher cryoglobulin activity. If so, the dysregulated expres- 
sion of galactosyltransferase involved in IgG galactosylation could be a significant 
genetic factor predisposing to the development of autoantibody-mediated tissue le- 
sions. 
Pathogenic potential of murine IgG3 monoclonal cryoglobulins 
Induction of cryoglobulin-associated glomerular and cutaneous vascular lesions 
by IgG3 monoclonal cryoglobulins 
Since most IgG3 mAb, independently of their specificities, formed cryoglobulins, 
we have explored whether cryoprecipitable IgG3 mAb are able to provoke tissue le- 
sions in normal mice after intraperitoneat injection of IgG3~secreting hybridomas. 
The 6-19 IgG3 anti-lgG2a RF mAb, derived from MRL-lpr/lpr mice, induces a re- 
markable pathology [15, 16]. At 5--7 days after the injection of 6-19 IgG3 RF hy- 
bridoma, vascular purpura, which is the most common manifestation i patients 
with cryoglobulinemia [3], develops in the skin of the ears, tails and footpads, 
which are not well protected by hair from thermic variations. Histological examina- 
tion of the skin lesions shows an intracapillary precipitation of cwoglobulins asso- 
ciated with an extensive infiltration of polymorphonuclear leukocytes (PMN) 
around small vessels and into subcutaneous tissue, and a massive extravasation of
erythrocytes (Fig. 1). Moreover, the 6-19 mAb induced a severe acute glomerulone- 
phritis. 111 the initial phase, the predominant gtomerular lesions are characterized by 
exudation of PMN and a mild proliferation of glomerular cells (Fig. 2A). A progres- 
sive accumulation of cryoglobulins in the subendothelial spaces of glomerular cap- 
illary walls leads to the formation of glomerular lesions resembling the "wire-loop" 
lesion typical of lupus nephritis (Fig. 2B). In contrast, lgM and IgGl class-switch 
variants of the 6-19 IgG3 mAb, which lose the cryoglobulin activity, fail to gener- 
ate skin and glomerular lesions (Fig. 2C) [18, 19]. This indicates that the cryopre- 
cipitating activity of IgG3 RF mAb is critically involved in the development of skin 
vasculitis and glomerulonephritis induced by the 6-t9 IgG3 RF mAb. This is con- 
sistent with the finding that among a panel of anti-IgG2a RF mAb of different Ig 
isotypes, including clonally related mAb bearing five different Ig isotypes, only the 
RF mAb able to cryoprecipitate - all from the IgG3 subclass - can induce skin and 
glomerutar lesions [25]. 
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Fig. 1k ,  B. Representative histological appearance of  skin vascular lesions of ears 7 days after the intra- 
peritoneal implantation of  the 6 -19  IgG3 RF hybr idoma cells into (BALB/c x MRL)FI  mice. Eeukocyto- 
elastic vasculitis is characterized by the infiltration of PMN and the exuavasat ion of  erythroeytes 
(PMN polymorphonnctear leucocytes). I-I#-E; A x 100. g x400 
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Fig. 2. A Representative histological appearance of glomerular lesions in mice sacrificed 5 days after the 
injection with 6-19 hybridoma cells9 Note the infiltration of PMN and increased glomerular cellularity. 
B Representative histological appearance of glomcrular lesions in mice killed 8 days after the 6 19 hybri- 
doma injection. Note the presence of PAS-positive deposits along the glomerular capillary walls, resem- 
bling "wire-loop'" lesions. C Representative histological appearance of gtomerulus from mice injected 
with hybridoma cells secreting 6-19 IgGl class-switch variant. In contrast to mice receiving hybridoma 
cells secreting 6-19 IgG3 mAb, no significant glomerular changes are observed. D Representative histo- 
logical appearance of glomerular lesions i  PMN-depteted mice 8 days after the injection with 6-19 hybri- 
doma cells. Their glomerular lesions are characterized by the voluminous intracapillary deposition of 
PAS-positive material which nearly occlude the capillary lumen, but the absence of "wire-loop" lesions 
(PAS periodic acid-Schiff). A H+E, B-D PAS; A-D xY00 
Since the 6-19 mAb has both anti-lgG2a RF and cryoglobulin activities, it is im- 
portant o determine the wle of the RF activity in the pathogenicity of the 6-19 mAb. 
To answer this question, we have determined the pathogenic effect of the 6-19 RF 
mAb in mice depleted of B lymphocytes by treatment with anti-IgM antibodies from 
birth or in SCID (severe combined immune deficiency) mice [43, 44]. Both B lym- 
phocyte-deficient mice, thus lacking the corresponding I G2a autoantigen, develop 
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Table 3. Development of glomerular nd skin vascular lesions in mice injected with 6-19 hyhridortm cells 
Mice GN Skin lesion 
Wild-type + + 
lg-deficient + - 
C3-deficient + + 
FcTR-deficiem j- _ 
PMN-depteted (+)~ - 
GN: Glomerulonephritis 
PMN-depteted mice fail to develop "wire-loop" glomeruh, r lesions, but present a different type of gtom- 
erular lesion, characterized by voluminous intracapillary thrombi [49] 
glomerular lesions as severe as those induced in immunologically normal mice, but 
completely fail to develop skin vascular lesions (Table 3). This strongly suggests that 
different pathological mechanisms govern the development of each tissue lesion. 
Both RF and cryoglobulin activities, and hence IgG3-IgG2a cryoglobulin immune 
complexes (IC) are required to induce cutaneous vascular lesions, while the renal 
pathogenicity is dependent on the cryoglobulin activity, but not on the anti-lgG2a RF 
activity. This conclusion is further supported by the finding that glomerular, but not 
cutaneous, lesions are similarly induced by a hybrid IgG3 mAb made of the 6-t9 
IgG3 H-chains and the L-chains from J558 anti-~l-3 dextran antibodies, devoid of 
the RF activity [43]. 
It should be emphasized, however, that only a fraction of IgG3 monoclonal cryo- 
globulins with other specifieities are able to provoke significant glomerular lesions, 
independently of serum levels of cryoglobulins [15, 16, 22]. This would well explain 
the fact that the quantity of circulating cryoglobulins does not always correlate with 
the degree of nephropathy in patients with cryoglobulinemia [45]. Since there is no 
mutation in the CT3 region of the pathogenic 6-19 mAb [25], it may be either that a 
particular V H sequence by itself is sufficient or that a unique combination of H- and 
L-chains is required for the expression of the renal pathogenicity of IgG3 cryogtobu- 
lins. Our preliminary results on transgenic mice expressing either the H-chain or 
both H- and L-chains of the 6-19 lgG3 RF mAb have shown similarly increased pro- 
duction of IgG3 cryoglobulins in both 6-19 H single and 6-19 H/L double-transgen- 
ic mice, despite their differences in L-chain composition of transgenic IgG3. Inter- 
estingly, only the 6-19 H/L double-transgenic mice expressing high levels of 6-19 
IgG3 RF spontaneously develop severe chronic glomerutonephritis. This result sttg- 
gests that the majority of IgG3 cryoglobulins resulting from a heterogeneous combi- 
nation of the transgenic 6-19 H-chains with endogenous L-chains in the 6-19 H sin- 
gle transgenic mice are poorly pathogenic. This strongly argues for the potential role 
of the ligand-binding property of the 6-19 RF mAb in the generation of glomerular 
lesions. An attractive hypothesis i  that the 6- t9  RF mAb may recognize a cross-re- 
active antigen present or implanted in glomemli, thereby provoking glomertflar in- 
flammation. The presence of autoantibodies reactive with glomemlar antigens has 
been reported in lupus-prone mice [46, 47], and the nephritogenic activity of some 
lgG3 anti-DNA mAb may be mediated through their interaction with nucleosomal 
antigens implanted in glomeruli [48]. However, a recent study has shown that glom- 
erular lesions similar to those induced by the 6-19 RF mAb are provoked by an IgG3 
(8A4) mAb against a hydrogenase from Wolinella succinogens, but not by its mutant 
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lacking three amino acids in the L-chain V region, though maintaining the same li- 
gand-binding specificity [23]. This could raise another possibility that the pathoge- 
nicity of IgG3 cryoglobulins can be determined by physicochemical properties, prob- 
ably related to the V region amino acid sequences, irrespective of their antigen-bind- 
ing specificity. 
Role of mast cells expressing I G Pc receptors, but not complement, 
in the development of skin vasculitis induced by 6-19 IgG3 RF monoctonal 
cryoglobulins 
PMN are the principal inflammatory cells in skin vascular lesions caused by 6-19 
RF mAb. As expected, no skin pur-puric lesions develop in mice depleted of PMN by 
the combined treatments of irradiation and anti-PMN mAb (Table 3) [49]. Notably, 
the treatment of mice with mAb against LFA-I (CDl la) or ICAM-1 (CD54) almost 
completely suppresses the development of 6-19 RF cryoglobulin-induced skin le- 
sions. Strikingly, mice depleted of C3 after treatment with cobra venom factor or ge- 
netically deficient in C3 still develop typical cutaneous vascular lesions (Table 3) 
[49]. Thus, complement activation does not play a major role in the pathogenesis of
PMN-dependent skin vascular lesions induced by 6-19 RF monoclonal cryoglobu- 
lins, despite the fact that IgG3-IgG2a IC are critically involved in the generation of 
cryoglobulin-associated skin vascular lesions. This suggests the involvement of other 
types of PMN chemoattractants in this model of cutaneous leukocytoclastic vasculi- 
tis. 
It should be also stressed that among a number of lgG3 monoclonal cryoglobu- 
lins studied, anti-IgG2a RF monoclonal cryoglobulins are the only mAb capable of 
inducing skin vascular lesions. The failure of non-RF IgG3 cryoglobulins to gener- 
ate skin vasculitis may be due to insufficient amounts of the IC formation by cer- 
tain mAb or related to different properties of IC generated. However, we have re- 
cently observed that mice injected with IgG3 anti-DNA hybridoma ceils fail to de- 
velop skin vascular lesions, despite the presence of substantial amounts of circulat- 
ing DNA-anti-DNA 1C and the development of severe glomerulonephritis (unpub- 
lished observation). The IC formation is probably a result of a massive release of 
nuclear antigens from implanted hybridoma cells. This raises the possibility that 
IgG2a, present in IgG3 RF IC, may play a crucial role in the pathogenesis of skin 
vascular lesions. Since the IgG2a, but not IgG3, isotype is known to efficiently in- 
teract with IgG Fc receptors (FcTR) [50], FcTR-dependent activation of effector 
cells, such as mast ceils, may be responsible for the generation of skin vasculitis, as 
in the case of the Arthus reaction [5l, 52]. In fact, mice deficient in FcyR are un- 
able to develop skin vasculitis following the implantation of 6-19 RF hybridoma 
cells (Table 3), but are capable of doing so after the transfer of wild-type Fc,/R-ex- 
pressing mast cells [53l. We speculate that the activation of mast cells, through the 
interaction of FcTR with IgG2a-containing l G3 cryoglobulin IC, may result in the 
release of inflammatory mediators that recruit and activate PMN, thereby generat- 
ing leukocytoclastic vascular lesions. Further analysis with mice deficient in tumor 
necrosis factor (TNP) has demonstrated that TNF released from activated mast cells 
is one of the mediators responsible for triggering this type of vasculitis [53], illus- 
trating the clinical significance of FcTR and TNF in IC-mediated autoimmune vas- 
cular syndrome. 
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Absent role of FcTR and complement activation in the development 
of glomerulonephritis induced by 6-19 lgG3 RF monoclonal cryoglobulins 
In a marked contrast to the pathogenetic mechanisms responsible for cutaneous leu- 
kocytoclastic vascular lesions, the development of glomerulonephritis induced by 
6-19 RF monoclonal cryoglobulins i not dependent on the activation of FcyR-ex- 
pressing cells (Table 3) [5311. As FcTR does not have any significant affinity to the 
[gG3 isotype [50], the lack of any inhibition of glomerular lesions in FcTR-deficient 
mice is consistent with the fact that the development of these glomerular lesions is 
independent of the formation of IgG3-IgG2a IC [43, 44]. It has been recently report- 
ed that FcyR-mediated inflammatory responses play an important role in the patho- 
genesis of lupus nephritis occurring ill (NZB • NZW)FI hybrid mice [54]. However, 
MRL-lpr/lpr mice deficient in FcyR still develop lethal glomerulonephritis as severe 
as that in conventional MRL-lpr/lpr mice (T. Saito, personal communication). Con- 
sidering that MRL-lpr/Ipr mice spontaneously generate xtremely large amounts of 
IgG3 cryoglobulins [13], these data suggest hat lupus nephritis occurring in MRL- 
Ipr/lpr mice might be more dependent on the production of lgG3 cry oglobulins, and 
thus less dependent on FcTR, unlike (NZB x NZW)FI hybrid mice. This is consistent 
with the observation that the progression of lupus nephritis in MRL-Ipr/lpr mice is 
con'elated with the production of IgG3 autoantibodies [55-57]. 
It should be stressed that C3-depleted or C3 null mutant mice still develop typical 
glomerular lesions following the implantation of 6-19 RF hybridoma ceils (Table 3) 
[49]. The presence of substantial PMN infiltration in glomerular lesions in C3-defi- 
cient )nice receiving 6-1.9 hybridoma cells indicates that the complement activation 
and subsequent C3 deposition do not play a major role in the PMN recruitment and 
subsequent generation of "wire-loop" glomerular lesions. This is in agreement with 
the lack of PMN infiltration and of "'wire-loop" lesions in IgG3 anti-DNP cryoglobu- 
lin-induced glomerular pathology, despite the presence of substantial C3 deposits 
[581 
Role of PMN in the development of "wire-loop" glomerular lesions induced 
by 6-19 IgG3 RF monoclonal cryoglobulins 
Like in skin vascular lesions, PMN are also the major inflammatory cells in the ini- 
tial phase of 6-19 RF-induced glomerular lesions. Significantly, mice depleted of 
PMN fail to develop "wiie-loop" lesions normally induced by the 6-19 mAb, but 
present a different ype of glomerular lesion (Table 3) [49]. Predominant glomerular 
changes are characterized by voluminous intracapillary thrombi that almost com- 
pletely obstruct he glomerutar capillary lumen (Fig. 2D). Examination by electron 
microscope reveals adiffuse plugging of glomerular capillaries by amorphous depos- 
its, while subendothelial deposits resembling "wire-loop" lesions are hardly detect- 
able in the PMN-depleted mice. It is of interest o note that these glomerular lesions 
are essentially identical to those induced by IgG3 anti-DNP monoclonal cryoglobu- 
lins, which are unable to provoke glomerular infiltration of PMN [58]. These results 
indicate a critical role for PMN in the generation of "wire-loop" glomerular lesions 
induced by the 6-19 RF monoclonal cryoglobulins. IgG3 RF mAb are capable of 
producing "wire-loop" lesions in the absence of corresponding I G2a autoantigens 
or C3. Therefore, the development of these two different ypes of glomerular lesions 
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is unlikely to be related to the different capacities of IgG3 cryoglobulins to induce IC 
formation and subsequent complement activation. 
It remains to be determined how glomerular deposits of 6-19 RF cryoglobulins lead 
to PMN infiltration and how PMN infiltration is involved in the generation of "wire- 
loop" glomemlar lesions. The ability of cryoglobulins to precipitate in the subendothe- 
lial space and/or in the glomerular capillary lumen is likely to be related to physico- 
chemical properties or ligand-binding properties of each individual cryoglobulin. Since 
mesangial cells are the initial site of cryoglobulin accumulation i glomeruli, a unique 
conformation of IgG3 cryoglobulins, either esulting from a particular pair of V H and 
V L amino acid sequences or from the specific binding to target antigens, may promote 
a direct interaction with and subsequent activation of mesangiat cells. An attractive hy- 
pothesis is that mesangial cells may express a receptor specific for the IgG3 isotype, 
but their interaction may be strongly influenced by the conformation of IgG3 cryogtob- 
ulins. The presence of IgG3-specific "FcyR", different from conventional Fc'IR, has 
been suggested by several studies [59, 60], although this has not yet been formally 
proved. If this is indeed the case, IgG3 uptake through the putative IgG3-specific 
"FcyR" by mesangial cells may be critical for determining the renal pathogenicity of
IgG3 cryoglobulins. Consequently, proinflammatory mediators released following the 
activation of mesangial cells probably play an active role in the PMN recruitment and 
subsequent activation, which leads to glomerular endothelial cell damage, ending up 
with "wire-loop" lesions. In this respect, we have recently observed a marked glomeru- 
lar induction of chemokines in mice injected with 6-19 hybridoma cells, but not in 
those injected with anti-DNP hybridoma ceils (unpublished observation). 
Future directions 
The development of a murine model of acute cryoglobulinemia associated with vas- 
cular and glomerular pathology following the implantation of hybridoma cetls secret- 
ing IgG3 mAb represents a good opportunity to further define the pathogenetic 
mechanisms leading to the lesions, and also to evaluate various therapeutic ap- 
proaches based on an interference at different levels of essential pathogenic path- 
ways. In addition, in view of the wide range of pathological manifestations seen in 
human patients with cryoglobulinemia, the generation of a chronic model of cryo- 
globulinemia might further help determine immunopathological onsequences a a 
result of the persistent and chronic presence of cryoglobulins, which cannot be stud- 
ied in hybridoma transplantation experiments. For this reason, we have recently es- 
tablished the transgenic mice expressing either H-chains or H- and L-chains of the 
IgG3 6-19 RF mAb. These transgenic mice expressing the [gG3 6-19 RF mAb in- 
deed develop severe chronic glomerulonephritis, whose lesions are highly heteroge- 
neous similar to those seen in lupus-prone mice, but distinct from those acutely in- 
duced by the implantation of 6- t9 hybridoma cells. More interestingly, these mice 
develop necrotizing arteritis, affecting small to medium-sized arteries in kidneys and 
skeletal muscle, but fail to develop cutaneous leukocytoclastic vasculitis, a typical 
vascular lesion induced by the implantation of 6-19 hybridoma cells. This indicates 
that a single cryoglobulin is able to induce different ypes of glomerular and vascular 
lesions, depending on the levels and kinetics of its production. Clearly, comparative 
analysis on the 6-19 H/L double transgenic mice and 6-19 hybridoma-injected mice 
would allow us to better define pathogenic mechanisms leading to the spontaneous 
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development of glomerular and vascular lesions as a consequence of the acute and 
chronic presence of pathogenic ryoglobutins. A better understanding of molecular 
and cellular events involved in the generation of cryoglobulin-mediated tissue le- 
sions could have clinical implications in the design of future therapeutic strategies. 
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